Bristol-Myers Squibb Company (BMY) nnounces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
Bristol-Myers Squibb Company (NYSE: BMY) FY 2026 Other Release
39 articles, transcripts, and reports
Bristol-Myers Squibb Company (NYSE: BMY) FY 2026 Other Release
Bristol-Myers Squibb Company (NYSE: BMY) FY 2026 Other Release
Bristol-Myers Squibb Company (NYSE: BMY) Sec Form 10K
Bristol-Myers Squibb Company (NYSE: BMY) Sec Form 8K
Bristol-Myers Squibb Company (NYSE: BMY) Q2 2025 Earnings Call dated Jul. 31, 2025 Corporate Participants: Charles E Triano — Senior Vice President and Head of…
Bristol-Myers Squibb Company (NYSE: BMY) Q3 2025 Earnings Call dated Oct. 30, 2025 Corporate Participants: Chuck Triano — Senior Vice President and Head of Investor…
Bristol Myers Squibb (NYSE: BMY) reported its third quarter 2025 earnings results today. Revenues increased 3% year-over-year to $12.2 billion. GAAP net income attributable to…
Bristol Myers Squibb (NYSE: BMY) reported its second quarter 2025 earnings results today. Total revenues inched up 1% year-over-year to $12.3 billion. Net earnings attributable…
Bristol Myers Squibb (NYSE: BMY) reported its third quarter 2024 earnings results today. Total revenues increased 8% year-over-year to $11.9 billion. Revenues grew 10%, excluding…
Bristol Myers Squibb (NYSE: BMY) reported first quarter 2024 earnings results today. Total revenues increased 5% year-over-year to $11.9 billion. When adjusted for foreign exchange…